Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
23 avr. 2020 07h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
13 avr. 2020 17h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
27 févr. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other...
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
20 févr. 2020 07h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
13 févr. 2020 11h40 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...